Skip to content
Open access

FIB-4, APRI, and AST/ALT Ratio Compared to FibroScan for the Assessment of Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 13 references

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is now the most prevalent chronic liver disorder globally. Liver fibrosis stage is the primary determinant of prognosis in NAFLD patients. FibroScan (transient elastography) is a validated non-invasive method for fibrosis assessment, but its availability remains limited in resource-constrained settings. Simple serum-based indices offer a potentially cost-effective alternative. Objectives: To evaluate and compare the diagnostic performance of FIB-4 score, APRI score, and AST/ALT ratio against FibroScan for the assessment of hepatic fibrosis in NAFLD patients. Methods: This hospital-based cross-sectional observational study enrolled 150 consecutive NAFLD patients at a tertiary care centre in Jaipur, India over 18 months (March 2024 – August 2025). All participants underwent FibroScan assessment and calculation of FIB-4, APRI, and AST/ALT ratio from standard biochemical parameters. Fibrosis was staged F0–F4 by transient elastography. Statistical analysis was performed using SPSS 29.0; a p-value <0.05 was considered significant. Results: The mean age was 51.41 ± 10.46 years; 62.67% were male. FibroScan-determined fibrosis distribution: F0 (40%), F4 (18%), F0–F1 (17.33%), F2–F3 (16.67%), F3–F4 (8%). All three serum indices — FIB-4, APRI, and AST/ALT ratio — showed statistically significant progressive increases with advancing fibrosis stage (all p < 0.001). In advanced fibrosis (F3–F4 and F4), 100% of patients exceeded the established high-risk thresholds for each index (FIB-4 ≥ 3.4; APRI > 1.5; AST/ALT ≥ 0.8). Mean FIB-4 scores rose from 1.16 ± 0.50 in F0 to 7.92 ± 1.03 in F4; APRI from 0.47 ± 0.16 to 2.62 ± 0.24; and AST/ALT ratio from 0.61 ± 0.15 to 1.50 ± 0.19. Conclusions: FIB-4, APRI, and AST/ALT ratio are reliable, low-cost, and widely accessible non-invasive markers that correlate strongly with FibroScan-determined fibrosis severity in NAFLD patients. FIB-4 demonstrated the greatest discriminative power for advanced fibrosis. These indices are recommended as initial fibrosis triage tools, with FibroScan reserved for patients in the indeterminate risk range.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.